cl-user
#363
Excellent. Thanks!
From the study, it looks like GDF15 is bad:
Our study also provided several candidate biomarkers for brain
aging. GDF15 was found to be the most significant plasma protein associated
with brain aging in our analysis, and was also associated with
chronological age and multiple age-related disorders. Notably,
previous studies have demonstrated the association of GDF15 with future
ACD, highlighting its significant role in neurodegenerative disorders.
GDF15 is a stress-regulated hormone and was upregulated in response
to environmental stress, being involved in energy homeostasis, insulin
resistance and mitochondrial dysfunction . […] it is an essential component
of the senescence-associated secretory
phenotype, which promotes neuroinflammation, synaptic dysfunction,
neuropathological changes, neuronal death and, ultimately, cognitive
impairment. Notably, due to the significant associations of GDF15 with
age and age-related disease, and its ubiquitous expression in the human
body, GDF15 is a more probable general biomarker of aging but not one
specific for brain aging.
BTW I’ve seen in a recent paper posted here that Metformin is increasing GDF15 production which is
another reason not to take it.
4 Likes
I follow Dale Bredesen on FB and he talks about his RESET program I wonder if anyone here is doing that? He has certain supps he does feel are helpful including alpha lipoic, melatonin, taurine, SPM resolvins, modified citrus pectins, l-arginine, pregnalone, curcumin, nattokinase, arteril HP, sildenafil,bergamot, sinc, vitamin D, magnesium threonate (this taken from a screen shot I did on a post he made)
4 Likes
Jay
#365
RapAdmin, That is an interesting article. Among other things such as Mounjaro and Tirzepatide a sleep medication for insomnia was mentioned, but I saw no reference to the name of the medicine. If anyone finds it, please post it. The exact reference is noted below:
Adding a sleep medication approved for insomnia helped, “but Simon really needs to tackle his sleep by improving his sleep hygiene with a more regular sleep schedule,” Isaacson said.
adssx
#366
Mounjaro and Tirzepatide are the same thing.
The sleep medication they refer to might be suvorexant? (there was some hype around it some time ago but I don’t know if it was confirmed to be neuroprotective)
1 Like
RapAdmin
#367
Study supports new blood-based biomarker to detect early brain changes leading to cognitive impairment and dementia
UCLA-led research confirms and expands on protein’s role in blood vessel permeability and steps leading to white matter injury and cognitive decline
To identify and follow blood vessel-related changes in the brain that contribute to cognitive impairment and dementia, researchers and clinicians typically rely on MRI to evaluate “downstream” biological markers – those at the end of a cascade of events. But a multicenter study(Link is external) led by UCLA researchers could lead to a cost-effective blood test to identify changes occurring near the top of the chain, potentially identifying at-risk patients at an earlier stage.
“We studied a protein in the blood that is critical in the formation of blood vessels but that also appears to play a role in vascular permeability associated with cognitive decline. Evaluating data from a large group of patients with a range of vascular risk profiles and cognition ranging from unimpaired to mild dementia, we found that plasma levels of this protein, placental growth factor (PlGF), could potentially be used as a biomarker to screen for and monitor cognitive impairment and dementia,” said Jason Hinman, MD, PhD, a vascular neurologist at UCLA Health, Interim Co-Director of the Mary S. Easton Center(Link is external) for Alzheimer’s Research and Care at David Geffen School of Medicine at UCLA(Link is external) and senior author of an article in Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association.
1 Like
“Obesity is now the top modifiable dementia risk factor in the U.S.,” reports the Journal of the American Medical Association in its latest bulletin. Obesity in midlife is now leading to more cases of dementia than any of the other usual suspects, including depression, smoking, diabetes, high blood pressure, physical inactivity, or low levels of education. About a third of dementia cases in America are now associated with some combination of these factors, with midlife obesity, physical inactivity and low education levels leading the way. According to the medical study, midlife obesity was a contributing factor to some 18% or just under 1 in 5 cases of dementia in America.
A decade ago obesity wasn’t even in the top three.
https://www.marketwatch.com/story/this-is-now-the-no-1-preventable-cause-of-alzheimers-in-america-11657553007
2 Likes
adssx
#370
Evaluating the causal association between type 2 diabetes and Alzheimer’s disease: a Two-Sample Mendelian Randomization Study 2024
Preprint
Our meta-analysis found no significant causal link between T2DM and AD (OR = 1.01, 95% CI: 0.99-1.03) with moderate heterogeneity (I² = 44.16%).
This meta-MR and MR analysis revealed no significant causal association between T2DM and AD, indicating that T2DM may not directly influence AD risk. Further research should explore other mechanisms linking these conditions.
Interesting 
2 Likes
Yes, but in one respect this result may be encouraging, because if it is true that anti-diabetic agents, such as SGLT2i, in patients with T2DM lower the incidence of AD, then they might in principle lower the incidence in people without T2DM. Otherwise one. might argue that the anti-diabetic agents lower the odds of AD, because AD is tied to T2DM. But if there is no connection between AD and T2DM, then these agents should be equally effective in people without T2DM.
9 Likes
" Results: Of 8 972 221 people who had died with occupational information, 3.88% (348 328) had Alzheimer’s disease listed as a cause of death. Among taxi drivers, 1.03% (171/16 658) died from Alzheimer’s disease, while among ambulance drivers, the rate was 0.74% (10/1348). After adjustment, ambulance drivers (0.91% (95% confidence interval 0.35% to 1.48%)) and taxi drivers (1.03% (0.87% to 1.18%)) had the lowest proportion of deaths due to Alzheimer’s disease of all occupations examined. This trend was not observed in other transportation related jobs that are less reliant on real time spatial and navigational processing or for other types of dementia. Results were consistent whether Alzheimer’s disease was recorded as an underlying or contributing cause of death. "
Too early to ditch Google Maps?
1 Like
adssx
#375
This is a bullshit study: as they say other transportation job didn’t show this association and people with cognitive impairment would leave these professions early.
3 Likes
Jay
#376
Tim, did you try visoluten? If so, any opinions? Thanks.
Led by researchers from the Karolinska Institute and the University of Gothenburg in Sweden, an international team looked at various biological signals to estimate brain age in 70-year-olds with no cognitive impairment.
What stood out from their analysis of 739 people was the importance of vascular (blood vessel) health when it comes to keeping brains looking young. Habits such as regular physical activity, sticking to a healthy diet, cutting out smoking, and managing glucose levels
6 Likes
You could probably throw keeping your blood pressure under control as well as reducing arterial plaque into the mix as well. In fact, they’re probably equally as important if not more so.
3 Likes
Tim
#380
Yes, @Jay, I tried Visoluten, but my retina specialist says my vision is stable, as it was before I tried the Visoluten. I avoid the bioregulators.
I think Khavison had success with epitalon and a few others, which earned him the coveted “Friend of Putin” award, and the success went to his head. He then went on to develop bioregulators, which, in my opinion, earned him an appointment with the executioner. The bioregulators are still made in Russia and sold to gullible westerners, but the truth–pravda–has been leaking out.
1 Like
Guest
#381
A very reputable US research lab (well recognized in the biomedical community) did discover another mechanisms, by which the production of plaque could be in theory inhibited. They did confirm this mechanisms in cell studies and genetically engineered animals. Consequently they did an AI driven unbiased screen for existing drugs, whose molecular structure are suitable as to target that mechanism.
The easily obtainable, cheap and side-effect free Ezitimibe came up on top. As a final step they compiled data from randomized clinical trials for Ezitimibe - in particular the follow up observational period after the clinical trials are done. They compared those people to a large set of demographical matches, adjusting for residual differences.
Ezetimibe users had an 86% lower incidence of Alzheimer’s dementia.
This still needs to be proven in dedicated RCT. The problem: ezetimibe is generic and nobody is going to finance that. But it doesn’t hurt to add ezetimibe to your daily dose of statins.
the free paper (June 2024):
a summary and reflection:
Happy New Year.
4 Likes
Ezetemibe lowering dementia risks makes perfect sense. There is a type of dementia related to lower blood flow to the brain due to arteriosclerosis. Ezetemibe would help prevent this. It makes perfect sense to me.
5 Likes
